Erlotinib [183321-74-6]
Referencia HY-50896-100mg
embalaje : 100mg
Marca : MedChemExpress
Erlotinib (CP-358774) is a directly acting EGFR tyrosine kinase inhibitor, with an IC50 of 2 nM for human EGFR. Erlotinib reduces EGFR autophosphorylation in intact tumor cells with an IC50 of 20 nM. Erlotinib is used for the treatment of non-small cell lung cancer. Erlotinib is a click chemistry reagent, itcontains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
Para uso exclusivo en investigación. No vendemos a pacientes.
Erlotinib Estructura química
No. CAS : 183321-74-6
This product is a controlled substance and not for sale in your territory.
Based on 84 publication(s) in Google Scholar
Other Forms of Erlotinib:
- Erlotinib Hydrochloride In-stock
- Erlotinib mesylate Obtener un presupuesto
- Erlotinib-d6 Obtener un presupuesto
- Erlotinib-13C6 Obtener un presupuesto
-
Erlotinib purchased from MedChemExpress. Usage Cited in: Cancer Med. 2019 Dec;8(18):7793-7808. [Abstract]
- Western blots of proteins expression in EGFR signaling pathways in LN229 and U87 cells with MYST1/GFP overexpression after erlotinib (200 ng/mL)/DMSO treatment.
-
Erlotinib purchased from MedChemExpress. Usage Cited in: Mol Oncol. 2018 Mar;12(3):305-321. [Abstract]
- Western blot analysis of total and phosphorylated EGFR expression in two breast cancer cells pretreated with different concentration Erlotinib for 4h.
-
Erlotinib purchased from MedChemExpress. Usage Cited in: Anal Chim Acta. 2018 Nov 22;1032:138-146. [Abstract]
- 30 min after EGF(100 ng/mL) and EGFP-sSH2(Arg)9 (5 μM) are added into the MDA-MB-468 cell culture medium, Erlotinib is added into the cell culture medium (100 nM), and the picture was collected at 30 min after Erlotinib treatment.
-
Erlotinib purchased from MedChemExpress. Usage Cited in: Front Pharmacol. 2018 Jun 21;9:660. [Abstract]
- By Western blotting, the α-SMA and palladin proteins are determined in cells that are pretreated with NF-κB (JSH-23), Wnt/β-catenin (XAV939), EGFR (erlotinib), p38 MAPK (TAK-715), and Smad3 (SIS3) inhibitors and are followed by TWEAK stimulation.
-
Erlotinib purchased from MedChemExpress. Usage Cited in: Oncogene. 2017 May 11;36(19):2643-2654. [Abstract]
- Effects of anti-cancer agents Oxaliplatin (25 mM), Erlotinib (25 mM) and cAMP inducer Forskolin (25 mM) on FOXO3 expression in Panc-1 cells are assessed for 72h (n=3).